B. Riley Comments on GENFIT S A/ADR’s Q1 2019 Earnings (NASDAQ:GNFT)

GENFIT S A/ADR (NASDAQ:GNFT) – Investment analysts at B. Riley reduced their Q1 2019 earnings per share estimates for GENFIT S A/ADR in a report released on Wednesday, June 12th. B. Riley analyst M. Mamtani now expects that the company will earn ($0.78) per share for the quarter, down from their previous estimate of ($0.73). B. Riley also issued estimates for GENFIT S A/ADR’s Q2 2019 earnings at ($0.89) EPS, Q3 2019 earnings at ($0.70) EPS, Q4 2019 earnings at ($0.98) EPS, FY2019 earnings at ($3.37) EPS, FY2020 earnings at ($3.90) EPS, FY2021 earnings at ($3.36) EPS, FY2022 earnings at $0.07 EPS and FY2023 earnings at $0.46 EPS.

GNFT has been the subject of a number of other research reports. Barclays began coverage on shares of GENFIT S A/ADR in a research report on Monday, April 22nd. They issued an “overweight” rating and a $55.00 target price for the company. Roth Capital reiterated a “buy” rating on shares of GENFIT S A/ADR in a research report on Tuesday, April 23rd. Svb Leerink began coverage on shares of GENFIT S A/ADR in a research report on Wednesday, April 24th. They issued an “outperform” rating and a $58.00 target price for the company. Leerink Swann began coverage on shares of GENFIT S A/ADR in a research report on Wednesday, April 24th. They issued an “outperform” rating and a $25.47 target price for the company. Finally, HC Wainwright decreased their target price on shares of GENFIT S A/ADR to $72.00 and set a “buy” rating for the company in a research report on Monday, April 22nd. Five research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average price target of $52.62.

Shares of GNFT opened at $21.53 on Friday. GENFIT S A/ADR has a 52-week low of $20.12 and a 52-week high of $26.25.

Hedge funds and other institutional investors have recently modified their holdings of the business. Morgan Stanley acquired a new stake in GENFIT S A/ADR in the 1st quarter valued at about $206,000. BlueCrest Capital Management Ltd acquired a new stake in GENFIT S A/ADR in the 1st quarter valued at about $240,000. New York State Common Retirement Fund acquired a new stake in GENFIT S A/ADR in the 1st quarter valued at about $267,000. Schonfeld Strategic Advisors LLC acquired a new stake in GENFIT S A/ADR in the 1st quarter valued at about $449,000. Finally, Dean Capital Investments Management LLC acquired a new stake in GENFIT S A/ADR in the 1st quarter valued at about $650,000. 15.31% of the stock is owned by institutional investors.

About GENFIT S A/ADR

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.

Recommended Story: What does cost of debt say about a company’s financial health?

Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply